Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Tumor model studies of /sup 131/I-tetracycline and other compounds

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:7193082
Iodine-131-tetracycline (/sup 131/I-TET) was prepared by allowing tetracycline hydrochloride to react with radioiodide in acidic methanol (labeling efficiency greater than 85 percent). This preparation was found to be stable at --4/sup 0/C for at least 72 hr. Some minimal in vivo breakdown did occur. The /sup 131/I-TET, /sup 67/Ga, and several /sup 99m/Tc compounds were studied in a rat hepatoma model. The incorporation of the radiopharmaceuticals into the tumor occurred rapidly, with peak levels at 0.5 and 24 hr after injection for /sup 131/I-TET and /sup 67/Ga, respectively. The clearance of the radiopharmaceutical from nonviable tumor was slower than for viable tumor, and by 72 hr after injection the greatest concentration of radioactivity appeared in the nonviable fraction. All normal tissues showed faster clearance than did tumor tissue, regardless of viability. Decreasing the quantity of /sup 131/I-TET injected increased the percent of uptake in the nonviable tumor tissue but had no effect on the viable tumor uptake. Of the /sup 99m/Tc compounds studied, the phosphates developed the highest tumor-to-background ratios. Unfortunately these ratios were not as high as those achieved for /sup 67/Ga or /sup 131/I-TET.
Research Organization:
Veterans Administration Hospital, San Diego, CA
OSTI ID:
7193082
Journal Information:
J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 17:4; ISSN JNMEA
Country of Publication:
United States
Language:
English